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Digital PCR as a tool to measure HIV 
persistence
Sofie Rutsaert1†, Kobus Bosman2†, Wim Trypsteen1, Monique Nijhuis2 and Linos Vandekerckhove1* 
Abstract 
Although antiretroviral therapy is able to suppress HIV replication in infected patients, the virus persists and rebounds 
when treatment is stopped. In order to find a cure that can eradicate the latent reservoir, one must be able to quantify 
the persisting virus. Traditionally, HIV persistence studies have used real-time PCR (qPCR) to measure the viral reservoir 
represented by HIV DNA and RNA. Most recently, digital PCR is gaining popularity as a novel approach to nucleic acid 
quantification as it allows for absolute target quantification. Various commercial digital PCR platforms are nowadays 
available that implement the principle of digital PCR, of which Bio-Rad’s QX200 ddPCR is currently the most used 
platform in HIV research. Quantification of HIV by digital PCR is proving to be a valuable improvement over qPCR as it 
is argued to have a higher robustness to mismatches between the primers-probe set and heterogeneous HIV, and for-
feits the need for a standard curve, both of which are known to complicate reliable quantification. However, currently 
available digital PCR platforms occasionally struggle with unexplained false-positive partitions, and reliable segrega-
tion between positive and negative droplets remains disputed. Future developments and advancements of the digital 
PCR technology are promising to aid in the accurate quantification and characterization of the persistent HIV reservoir.
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Background
During antiretroviral therapy (ART), HIV can persist for 
decades in latently infected CD4  +  T cells as proviral 
DNA integrated in the human genome. If ART is inter-
rupted, the proviral reservoir fuels rebound viremia and 
is therefore considered a major obstacle to HIV cure [1]. 
HIV cure efforts aim to reduce the size and replication-
competence of the reservoir by evaluating the success of 
HIV cure interventions, which is represented by an effect 
on the level of proviral DNA and/or cell-associated viral 
RNA. The standard tool to quantify HIV DNA and cell-
associated viral RNA has been real-time PCR (qPCR). 
However, digital PCR has become a promising quanti-
fication strategy that combines absolute quantification 
with high sensitivity [2]. Digital PCR is based on the 
concept of limiting dilution where target molecules are 
randomly divided among a multitude of partitions. After 
PCR amplification, partitions that contain a target mole-
cule accumulate fluorescence whereas partitions without 
target remain low in fluorescence (Fig. 1). A threshold is 
applied to the partitions, which divides the partitions into 
a positive and a negative population. The ratio between 
the number of positive and negative partitions is used to 
calculate the absolute number of target molecules, cor-
rected for the chance that partitions are shared by mul-
tiple target molecules by the Poisson distribution law [2]. 
The first steps towards digital PCR were taken 30  years 
ago when the concept of limiting dilution and Poisson 
distribution were applied to detect rare targets [3–5]. In 
the field of HIV research, Simmonds et al. [6] combined 
PCR with limiting dilution to quantify the proviruses 
in HIV-infected cells. The term ‘digital PCR’ was intro-
duced by Vogelstein in [7] to identify specific mutated 
sequences in a minor fraction of a cell population. Nowa-
days digital PCR is a widely accepted quantification tool 
and applied in many fields.
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Digital PCR platforms
The key principle of digital PCR is the distribution of a 
sample among multiple partitions. Originally, parti-
tions were created by manually distributing a sample 
over a number of wells [7]. Nowadays, manual partition-
ing is applied in case of complex protocols with a nested 
approach that cannot be adopted to an automated plat-
form, such as the digital PCR described as a manual 
repetitive sampling protocol that is used to measure inte-
grated HIV DNA [8, 9]. However, manually generating 
multiple partitions is very time-consuming and laborious. 
The past decade automated systems have emerged and 
different technologies and methods are being explored 
by various companies for digitizing PCR (for an overview, 
see Table  1). Currently available digital platforms dif-
fer in number of partitions, method of generating parti-
tions or required specialized equipment. Partitions can 
be generated in a pre-manufactured array: BioMark™ 
HD System (Fluidigm) provides a wide range of special-
ized digital integrated fluidic circuits (IFCs) arrays where 
the sample is dispensed in a well and distributed over 
multiple individual reaction chambers. QuantStudio 
3D (Life Technologies/Applied Biosystems™) employs 
a silicon chip that consists of a single array of individ-
ual reaction wells onto which the sample is dispensed. 
 CONSTELLATION® Digital PCR System (Formu-
latrix) utilizes a microplate where connecting channels 
are isolated into individual microfluidic chambers by a 
seal-compressing roller. In contrast to these array-based 
approaches, other digital PCR platforms such as the 
QX200™ Droplet Digital™ PCR (ddPCR) and RainDrop 
plus™ Digital PCR system (RainDance™ technologies) 
use water-in-oil emulsion chemistry to create parti-
tions. The aqueous phase consisting of primers, probe 
and supermix, sample, and a mineral oil is loaded into a 
specifically designed holder. The droplet generator uses 
microfluidics to create a pressure that draws the aque-
ous and oil phase into the output channel, forming the 
droplets in the process. Each droplet is read one by one 
in a specialized droplet reader. Finally, Naica system from 
Stilla combines both the array and emulsion approaches. 
Fig. 1 Digital PCR. In digital PCR the sample is divided in multiple partitions. After PCR amplification, partitions containing the target produce a 
signal and are assigned positive. Discriminating between positive and negative partitions remains challenging and threshold setting can influence 
quantification, especially in low target settings
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In this system, a sample runs through the channels of a 
chip and droplets are created inside the chip.
Challenges and benefits of droplet digital PCR
There are multiple digital PCR platforms, but over the 
past years, the QX200 has steadily become the most 
widely used digital PCR platform across all research 
fields (Fig. 2). Therefore, in this review we will focus on 
the QX200 ddPCR from Bio-Rad to discuss challenges 
and benefits of digital PCR. It should however be noted 
that challenges with threshold determination and false-
positives are not exclusively observed with the ddPCR 
from Bio-Rad but seem to be related to other digital plat-
forms as well [11–15].
Threshold determination
In ddPCR generated droplets are identified as positive or 
negative based on a threshold at a certain fluorescence 
level and this ratio is used to calculate target abundance 
using Poisson-statistics. Therefore, determining a correct 
threshold is crucial for reliable quantification (Fig.  1). 
Defining a threshold is complicated by droplets with an 
intermediate fluorescence, termed as rain, which are puz-
zling to assign to the either positive or negative popula-
tion. For the frequently used Bio-Rad ddPCR system, the 
QuantaSoft software offers an undisclosed method for 
automated threshold assignment and manual threshold 
setting by the end-user. The automated analysis often 
assigns thresholds so strict that a cloud of droplets is 
appointed positive that based on their low fluorescence is 
expected to be negative [16]. Alternatively, user-defined 
thresholds may be applied but these are generally not 
advised as they impair an unbiased interpretation of digi-
tal PCR data. Threshold setting can be challenging since 
the separation between positive and negative droplets 
may depend on many factors, such as the quality and 
quantity of the input sample, melting temperature and 
length of primers and probe, mismatches between the 
assay and target sequences, time between droplet gen-
eration and readout, pipetting precision, type of fluores-
cent reporter and type of quencher. Several algorithms 
have been developed by end-users that aim to offer more 
data-driven approaches to set thresholds. First, cluster-
ing methods were developed by Strain et  al. and Jones 
et  al. based on k-nearest neighbor-joining [17, 18]. The 
method of Strain et al. defines the median and variance 
of the negative and positive clouds to assess the statisti-
cal likelihood that outliers should be included in either 
cloud (p  <  0.1). Jones et  al. developed “definetherain” 
that uses negative and positive control samples to iden-
tify the two clouds. Subsequently, the mean fluorescence 
minus or plus three times its standard deviation is used 
as thresholds that are applied to the samples. Both these 
clustering methods calculate a threshold for each cloud 
of droplets and exclude intermediate fluorescent droplets 
from further analysis. In contrast, Dreo et  al. proposed 
a single threshold determination method since droplets 
with intermediate fluorescence intensity can hold true 
positive droplets [19, 20]. This global manual threshold 
is defined as the mean fluorescence signal in the NTCs 
(no template controls) plus a number of standard devia-
tions until one positive droplet remains in the NTCs [19]. 
These described methods assume a normal (binomial) 
distribution of the negative and positive clouds and do 
not account for shifts in baseline fluorescence between 
droplet populations of different samples. However, dis-
tribution fitting experiments and normality testing shows 
that droplet clouds do not follow a normal distribution 
and cannot be described by a single family of distribu-
tions. Furthermore, baseline fluorescence of the nega-
tive cloud has been shown to vary between samples and 
influence quantification [16]. Therefore, an alternative 
Fig. 2 The use of droplet digital PCR during the period 2011–2017, reported as percentage of total number of digital PCR articles cited in PubMed 
(search terms: “digital PCR” or dPCR, droplet digital PCR” or ddPCR)
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thresholding method was devised by Trypsteen et al. [16] 
that assigns a threshold regardless of the many factors 
that may affect the intensity and distribution of droplet 
fluorescence. This method, ddpcRquant, feeds data from 
negative controls to a generalized extreme value model 
and applies this threshold to the samples. The algorithm 
does not make assumptions of the underlying distribu-
tion of the droplet populations and accounts for base-
line shifts. Alternatively, Lievens et al. [20] determine the 
threshold based on the shape of the fluorescence den-
sity peaks but to account for the possibility that clouds 
are not normally distributed set the threshold above the 
uppermost limit of the negative cloud. Recently, a novel 
method, “Umbrella”, was published that does not apply 
hard thresholding, but applies a model-based cluster-
ing and takes partition-specific classification probabili-
ties into account to produce a final quantification result 
[21]. Threshold setting remains a challenging but crucial 
task. It is difficult to establish whether or not intermedi-
ate droplets represent true targets that should be used 
for analysis, since the current generation of ddPCR is 
not fitted with a fluorescence intensity sorter to allow for 
target confirmation by for example sequencing. Recent 
evidence however suggests that intermediate drop-
lets should be considered to contain target molecules, 
as decreased amplification efficiency may arise from a 
suboptimal annealing temperature [22] or mismatches 
between the assay and the target sequence [16]. Further-
more, several studies that investigated ddPCR sensitivity 
have used a user-defined threshold that allocates rain to 
the positive fraction of droplets, and doing so have found 
results that are on par with the input reference and qPCR 
results [11, 20, 23, 24].
False‑positives
Regardless of the method that is used to assign a thresh-
old, currently available digital PCR platforms including 
the QX200 suffer from the observation of false-positive 
partitions and therefore false-positive results [11, 16, 
18, 23–25]. One out of three wells of negative controls 
with no template had 2 or 3 positive droplets (0.16–0.22 
copies/reaction) for HIV-1 RNA assay described by 
Kiselinova et  al. [23]. These droplets had a similar fluo-
rescence level as positive droplets in patients samples. 
The origin of these errors remains unclear and various 
hypotheses have been proposed. False-positive droplets 
can arise from contaminations or disturbed droplets that 
merge together, their joint fluorescence leading to a drop-
let with a higher baseline fluorescence that is miscalled as 
positive.
False-positive droplets can pose a threat to reliable HIV 
DNA quantification in settings with low HIV DNA con-
centrations such as mother-to-child transmission, early 
treatment initiation and allogeneic stem cell transplan-
tation (alloSCT). AlloSCT is currently the only known 
approach by which the HIV reservoir can be drastically 
reduced. Following a successful stem cell transplantation, 
patients are kept on ART and are monitored for HIV 
DNA levels, but reliable ascertainment of remainder HIV 
DNA is a challenge, especially when the interpretation of 
true-positive droplets is obscured by false-positive ones. 
Same holds true for ART-treated children, which may 
have initiated ART early after birth based on the HIV-sta-
tus of their mother whereas uncertainty may exist if the 
infection was transmitted from mother to child. In these 
seronegative children, HIV DNA is the only proof of HIV 
infection and therefore the only justification for treat-
ment with ART. However, confirmation of the presence 
of HIV DNA is challenging since patients who initiated 
ART early after infection are known to have small reser-
voirs and sample volumes are restricted in case of young 
children, which reduces the statistical power to assess 
the presence of HIV DNA. Therefore, false-positives can 
unrightfully lead to confirmation of HIV infection and 
continuation of ART and it is not advised to use digital 
PCR if the question is to discriminate between presence 
or absence of HIV DNA [11]. Since only a minor fraction 
of all potential CD4 positive target cells carry HIV DNA, 
a large number of cells need to be tested in order to be 
able to reliably quantify HIV DNA concentrations. High 
concentrations of total DNA however affect the viscos-
ity of the aqueous phase and complicate the formation of 
droplets. The amount of DNA that can be loaded into a 
single reaction is therefore restricted [18, 26]. Research-
ers who aim to report an HIV DNA concentration in a 
million CD4-cells are required to split the target DNA 
among a number of reactions, thereby increasing the risk 
of detecting false-positive droplets and influencing final 
HIV DNA concentration outcome. This effect is even 
greater when samples are used in which HIV DNA is 
even less abundant, such as PBMCs, whole blood, dried 
blood spots or tissue biopsies.
Advantages
Apart from the issue of false-positives, digital PCR 
has shown to be equal or superior to qPCR in several 
aspects. One major advantage is that digital PCR pro-
duces direct absolute quantification. The absolute quan-
tification results produced by digital PCR eliminate the 
need for a standard curve in case of DNA quantifications 
and comparisons of RNA quantifications. Of note, RNA 
quantification represents cDNA molecules and should 
therefore be corrected for cDNA synthesis efficiency 
[27]. Accurate quantification by qPCR is based on the 
quality of the standard curve: instability of the standard 
curve can lead to inaccurate HIV DNA quantification 
Page 6 of 8Rutsaert et al. Retrovirology  (2018) 15:16 
[28]. Additionally, Cq values in qPCR that arise from the 
standard and the samples are based on amplification effi-
ciencies, and several factors may confound their correct 
interpretation. Amplification efficiency may be affected 
by inhibitors, amount of total DNA that is loaded as well 
as variation between the primer/probe and the patient’s 
viral sequence, and these factors may unrightfully ele-
vate the Cq values. In qPCR, such mismatches would 
increase the Cq and in turn present a target abundance 
that is lower than the actual input. In ddPCR however, a 
reduced amplification efficiency leads to less fluorescence 
at end-point. As long as end-point fluorescence remains 
above the assigned threshold and the ratio between posi-
tive and negative fraction of droplets is unaltered, mis-
matches between assay and target are allowed as they do 
not affect the quantification outcome [16, 29, 30]. Toler-
ance to target sequence variation is especially crucial for 
HIV quantification as a higher chance of mismatches 
with the primer–probe set is to be expected due to high 
heterogeneity of the virus [31]. Besides the robustness of 
ddPCR with respect to inhibition and reduced amplifi-
cation efficiency, a higher precision and reproducibility 
was observed for ddPCR in comparison to qPCR [18, 
32]. This is especially crucial in HIV cure efforts where 
the aim is to detect potential effects of the interventions 
on the HIV reservoir. However, it is important to note 
here that contradicting findings have been published that 
observed a higher sensitivity of the qPCR platform [23, 
33]. In duplex digital PCR experiments on linked tar-
gets, a minority of partitions was observed in which only 
one out of two assays demonstrated amplification [34]. 
It remains however unclear whether this observation is 
artificial due to DNA shearing and physical separation 
of supposed linked targets, or genuine failure to amplify 
due to assay-specific inhibitors, DNA degradation or ter-
tiary structures. Furthermore, in case of genuine failure 
to amplify it is currently unclear whether this potential 
mode of target underestimation pertains to digital PCR 
alone or if similar mechanisms are at play in case of (q)
PCR.
Applicability and future perspectives
HIV reservoir measurement by digital PCR has been 
used to measure the effects of early treatment initiation 
[35–38], therapeutic vaccination [39–41], allogenic stem 
cell transplantation [42], structured treatment interrup-
tions [40, 43], immunization by broadly neutralizing 
antibodies [44], latency reversing agents (LRA’s) [41, 
45–49], and other novel therapeutic agents [50–52]. The 
concept of digital PCR is well-established but automated 
platforms and implementations in HIV quantification are 
relatively recent and the field is looking forward to future 
advancements. Where some platforms limit the number 
of specialized devices needed  (CONSTELLATION® 
Digital PCR System microplate from Formulatrix), other 
companies are working on a multiplex system up to 6 
colors (Naica system from Stilla) or enable the analysis 
of multiple samples in a single run (QX200 from Bio-
Rad). The combination of these features combined in 
a single device with a high-throughput workflow and 
elaborate multiplex system is desired. In addition, data 
analysis and threshold setting should be further devel-
oped in order to keep up with advances in multiplex-
ing. Considering the observed false-positive partitions 
in current digital PCR platforms, quality control of the 
partitions is crucial. Naica system from Stilla currently 
allows visual inspection of the size and geometry of 
a single crystal droplet and the exclusion of those that 
are aberrant. The QX200 digital PCR platform may ben-
efit from an integrated fluorescence sorter for post-PCR 
analysis of droplets. Such a feature would improve our 
understanding of the nature of suspected false-positive 
droplets by allowing post-PCR sequencing to verify if 
fluorescence is the cause of PCR or rather through the 
acquisition of fluorescent dust or debris. In addition, 
post-PCR sorting of single-cell droplets may improve 
our understanding of the dynamics involved in latency 
[47]. Yucha et al. demonstrated that the QX200 cartridge 
can be used to create single-cell-droplets, after which 
HIV RNA was quantified using standard digital PCR 
protocol. Using a blunt needle, they manually selected 
positive droplets for post-PCR sequencing of HIV ENV 
and human CCR5, and future experiments may even 
investigate HIV integration site or viral protein pro-
duction. This holistic approach to HIV latency research 
holds great promise, yet requires specialized equipment 
and trained personnel and would therefore benefit from 
a fluorescence sorter that is integrated into the QX200 
reader. Although digital PCR allows the precise quanti-
fication of HIV DNA and RNA in patients, it does not 
enable researchers to gain information about the repli-
cation-competence of the reservoir. Whereas the cell 
culture based viral outgrowth assay is an underestima-
tion of the true viral reservoir, HIV measured by PCR is 
an overestimation because it counts the non-replication 
competent viruses as well [53]. Multiplexed ddPCR may 
however improve our understanding of the gap between 
viral outgrowth and PCR-based assays. Anderson et  al. 
[54] used a multiplexed ddPCR to observe an increase of 
the LTR:gag ratio during time on treatment, which can 
be explained by elimination of replication-competent 
viruses or clonal expansion of non-replication compe-
tent viruses. Additionally, multiplexed ddPCR could aid 
in determining the number of times an HIV sequence 
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has been clonally expanded. Clonal expansion and its 
specific HIV integration site is an international focus 
point since it is linked to persistence of HIV-infected 
cells [55]. However, integration site analysis is labori-
ous and expensive but designing a multiplex ddPCR 
that targets HIV and the human sequence adjacent to 
HIV, clonal expansion of that specific HIV sequence can 
be calculated based on the increase of double-positive 
droplets relative to expected number based on chance 
[56]. In summary, digital PCR has proven to be a valu-
able new technology and with additional improvements 
in prospect it is likely to mature into an indispensable 
tool in future HIV research.
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